

WELCOME
Given its central role in immune modulation, the skin is a critical target for therapeutic intervention in food allergy and other immunologic disorders.1 Epicutaneous immunotherapy (EPIT) is a noninvasive, innovative approach that aims to re-train the immune system over time.1-3
MECHANISM OF ACTION (MOA)
EPIT uses the tolerogenic immune properties of the skin to induce desensitization while limiting systemic allergen exposure.*
Treg, regulatory T cell.
*Based on animal model data.
WHY PEANUT?
The annual incidence of peanut allergy has increased over time.8
Reactions can be unpredictable and severe, including the potential for anaphylaxis.9,10
Peanut allergy exerts a substantial burden that often lasts a lifetime.11,12
CLINICAL TRIALS
In our lead program for peanut allergy17:
>1.1
MILLION
patches applied
~1600
children aged 1 to 7 years treated
ONGOING
Supplemental Safety
~480 patients
6-month phase 3 DBPC + 18-month OLE
COMPLETED
Efficacy & Safety
654 patients
12-month phase 3 DBPC
ONGOING
Open-Label Extension
Efficacy & Safety
507 patients
24-month OLE (up to 36 months total follow-up)
COMPLETED
Efficacy & Safety
362 patients
12-month phase 3 DBPC
COMPLETED
Efficacy & Safety
266 patients
24-month OLE (36 months total follow-up)
ONGOING
Efficacy & Safety
~250 patients
48-month phase 2 open-label
DBPC, double-blind, placebo-controlled; OLE, open-label extension.
PIPELINE
DEVELOPMENT STAGE
Program & Indication
Food Allergy
VIASKIN Peanut Patch
(DBV712)
Peanut Allergy
Ages 4-7 years
Ages 1-3 years
Ages 6-12 months*
VIASKIN Milk Patch
(DBV135)
Cow's Milk Allergy
Ages 2-17 years
Autoimmune & Inflammatory Disorders
Celiac Disease
Multiple Programs
*Study assessing the achievement of ad-lib dietary peanut consumption following a minimum of 3 years of treatment in patients enrolled at 6 through 12 months of age. Ad-lib consumption will be defined as the consumption amount and frequency that meets the treatment goals of the family or suggests that permanent tolerance has been achieved.17,23
Epicutaneous immunotherapy and VIASKIN® Peanut Patch are under clinical investigation and have not yet been approved by any health or regulatory authority.
DBV is a global, clinical-stage biopharmaceutical company committed to transforming the lives of children and families living with the daily challenges of food allergy.
THANK YOU
Scan the QR code or visit
dbv-technologies.com
to find out more.
Epicutaneous immunotherapy and VIASKIN® Peanut Patch are under clinical investigation and have not yet been approved by any health or regulatory authority.
References: 1. Hervé PL et al. Front Allergy. 2023;4:1290003. 2. Ravindran M et al. Allergy. 2025;80(1):63-76 3. Dioszeghy V et al. J Immunol. 2011;186(10):5629-5637. 4. Hund SK et al. Front Immunol. 2025;16:1572283 5. Hwang DW et al. Immunother Adv. 2022;2:1-7. 6. Fleischer DM et al. Allergy Asthma Proc. 2020;41(5):326-335. 7. Mondoulet L et al. J Allergy Clin Immunol. 2015;135(6):1546-1557. doi:10.1016/j.jaci.2014.11.028 8. Mahr TA et al. J Allergy Clin Immunol Pract. 2021;9(4):1683-1694.e5. 9. Muraro A et al. Clin Transl Allergy. 2021;11(8)e12064. 10. Cherkaoui SY et al. Clin Transl Allergy. 2015;5:16. 11. Gupta RS et al. Pediatrics. 2018;142(6):e20181235. 12. Warren C et al. J Allergy Clin Immunol. 2021;147(6):2263-2270.e5. 13. Dahlsgaard KK et al. Ann Allergy Asthma Immunol. 2025;134(5):525-532. 14. Schauberger EM, Singh AM. J Food Allergy. 2020;2(1):59-63. 15. Lieberman JA et al. Allergy. 2021;76(5):1367-1384. 16. Nocerino R et al. Children (Basel). 2024;11(12):1485. 17. Data on File. DBV Technologies. 18. Clinicaltrials.gov. Accessed November 6, 2025. https://clinicaltrials.gov/study/NCT07003919 19. News release. DBV Technologies. December 16, 2025. 20. Clinicaltrials.gov. Accessed November 6, 2025. https://clinicaltrials.gov/study/NCT05741476 21. Greenhawt M et al. N Engl J Med. 2023;388(19):1755-1766. 22. Greenhawt M, Wang J, Du Toit G, et al. Poster Presented at: Eastern Food Allergy & Comorbidity Conference 2025: Palm Beach, FL. 23. News release. DBV Technologies. February 2, 2026.
© 2026 DBV Technologies. VIASKIN® is a registered trademark of DBV Technologies. All rights reserved. 2026-MLR-088 https://dbv-technologies.com